|
1) 石川司朗, 青墳裕之, 越後茂之, 他. 小児心不全薬物療法ガイドライン. 日本小児循環器学会雑誌. 2001; 17: 501-12
|
|
|
|
|
2) The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: 1429-35
|
|
|
|
|
3) The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 293-302
|
|
|
|
|
|
4) Hazama K, Nakazawa M, Momma K. Effective dose and cardiovascular effects of cilazapril in children with heart failure. Am J Cardiol. 2001; 88: 801-5
|
|
|
|
|
|
5) Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of captopril in children with congestive or restrictive cardio-myopathy. Circulation. 1991; 83: 523-7
|
|
|
|
|
|
6) Stem H, Weil J, Genz T, et al. Captopril in children with dilated cardiomyopathy: acute and long-term effects in a prospective study of hemodynamic and hormonal effects. Pediatr Cardiol. 1990; 11: 22-8
|
|
|
|
|
|
7) Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol. 1993; 14: 9-12
|
|
|
|
|
|
8) 村上智明, 八鍬 聡, 上野倫彦, 他. 両方向性グレン手術・共通房室弁置換術後重症心不全に対しベータ遮断薬を導入し改善した心房錯位症候群の1例. 心臓. 2003; 35: 170-4
|
|
|
|
|
9) Mori Y, Nakazawa M, Tomimatsu H, et al. Long-term effect of angiotension-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. J Am Coll Cardiol. 2000; 36: 270-5
|
|
|
|
|
|
10) Seguchi M, Nakazawa M, Momma K. Effect of enalapril on infants and children with congestive heart failure. Cardiol Young. 1992; 2: 14-9
|
|
|
|
|
|
11) 村上智明, 八鍬 聡, 武田充人, 他. 大動脈二尖弁を基礎疾患とした大動脈弁閉鎖不全にアンジオテンシン変換酵素阻害薬が著効した一例. 日本小児臨床薬理学会雑誌. 2008; 19: 147-8
|
|
|
|
|
|
12) Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355: 1582-3
|
|
|
|
|
|
13) Witherow FN, Helmy A, Webb DJ, et al. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhi-bition in patients with heart failure. Circulation. 2001; 104: 2177-81
|
|
|
|
|
|
14) McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362: 767-71
|
|
|
|
|
|
15) Hirooka K, Koretsune Y, Yoshimoto S, et al. Twice-daily administration of a long-acting angiotensin-converting enzyme inhibitor has greater effects on neurohumoral factors than a once-daily regimen in patients with chronic congestive heart failure. J Cardiovasc Pharmacol. 2004; 43: 56-60
|
|
|
|
|
|
16) Izzedine H, Fardet L, Launay-Vacher V, et al. Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidi-uretic hormone: case report and review of the literature. Clin Pharmacol Ther. 2002; 71: 503-7
|
|
|
|
|
|
17) Shaikh ZH, Taylor HC, Maroo PV, et al. Syndrome of inappropriate antidiuretic hormone secretion associated with lisinopril. Ann Pharmacother. 2000; 34: 176-9
|
|
|
|
|
|
18) Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-17
|
|
|
|
|
|
19) Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21
|
|
|
|
|
|
20) Cosin J, investigators T. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fall. 2002; 4: 507-13
|
|
|
|
|
|
21) Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxy-peptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000; 87: E1-9
|
|
|
|
|
|
22) Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417: 822-8
|
|
|
|
|
|
23) Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006; 47: 718-26
|
|
|
|
|
|
24) Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Car-vedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349-55
|
|
|
|
|
|
25) Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007; 298: 1171-9
|
|
|
|
|
|
26) Azeka E, Franchini Ramires JA, Valler C, et al. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol. 2002; 40: 2034-8
|
|
|
|
|
|
27) Bajcetic M, Kokic Nikolic A, Djukic M, et al. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. Clin Ther. 2008; 30: 702-14
|
|
|
|
|
|
28) Abdulla J, Kober L, Christensen E, et al. Effect of beta-blocker therapy on functional status in patients with heart failure--a meta-analysis. Eur J Heart Fail. 2006; 8: 522-31
|
|
|
|
|
|
29) 盛一享徳, 仲西正憲, 村上智明. パルボウイルス心筋炎による心不全に対するβ遮断薬の効果. 日本小児科学会雑誌. 2007; 111: 765-9
|
|
|
|
|
|
30) Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004; 147: 324-30
|
|
|
|
|
|
31) Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005; 112: 2426-35
|
|
|
|
|
|
32) Cohn JN, Tognoni G, Investigators. VHFT. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-75
|
|
|
|
|
|
33) 八鍬 聡, 盛一享徳, 武田充人, 他. 塩酸オルプリノンが小児左室機能に及ぼす影響の検討 術後症例を対象として. 呼吸と循環. 2005; 53: S4-5
|
|
|
|
|
|
34) Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998; 339: 1810-6
|
|
|
|
|
|
35) Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J. 2002; 66: 149-57
|
|
|
|
|
36) Scammell AM, Arnold R, Wilkinson JL. Captopril in treatment of infant heart failure: a preliminary report. Int J Cardiol. 1987; 16: 295-301
|
|
|
|
|
|
37) Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Child. 1988; 63: 360-3
|
|
|
|
|
|
38) Shaddy RE, Teitel DF, Brett C. Short-term hemodynamic effects of captopril infants with congestive heart failure. Am J Dis Child. 1988; 142: 100-5
|
|
|
|
|
|
39) Montigny M, Davignon A, Fouron JC, et al. Captopril in infants for congestive heart failure secondary to a large ventricular left-to right shunt. Am J Cardiol. 1989; 63: 631-3
|
|
|
|
|
|
40) Seguchi M, Nakazawa M, Momma K. Further evidence suggesting a limited role of digitalis in infants with circulatory congestion secondary to large ventricular septal defect. Am J Cardiol. 1999; 83: 1408-11, A8
|
|
|
|
|
|
41) Nakazawa M, Takahashi Y, Aiba S, et al. Acute hemodynamic effects of dopamine, dobutamine, and isoproterenol in congested infants or young children with large ventricular septal defect. Jpn Circ J. 1987; 51: 1010-5
|
|
|
|
|